2.Other agents within the class of GLP-1 RA or GLP-1 RA /GIP RA dual agonists can be used for the improvement of glycemic control with a low risk of both hypoglycemia and beneficial effects of weight loss in obese people with T2DM and CKD (Grade 1A). This evidence concerns the gene GLP1R and chronic kidney disease.